Dostarlimab
Jemperli (dostarlimab) is an antibody pharmaceutical. Dostarlimab was first approved as Jemperli on 2021-04-21. It has been approved in Europe to treat endometrial neoplasms. It is known to target programmed cell death protein 1.
| Trade Name | Jemperli |
|---|---|
| Common Name | Dostarlimab |
| Indication | endometrial neoplasms |
| Drug Class | Monoclonal antibodies: immunomodulating |
